XXXX , @entity900 , and protracted infusion of @entity1487 (ECF) in advanced @entity1419 .

@entity1 @entity137 @entity882 @entity548 @entity1259 @entity900 @entity281 @entity1398 @entity1419 @entity1487
PURPOSE: @entity1419 usually presents late in the clinical course and has a poor prognosis. No effective systemic therapy is currently available. This study aimed to determine the efficacy and @entity137 of the ECF regimen ( @entity1259 , @entity900 . and 24-h continuous infusion of @entity1487 ) in advanced @entity1419 . @entity1 AND METHOD: On day 1, @entity1259 50 mg/m(2) and @entity900 60 mg/m(2) were administered i.v., repeated every 21 days. @entity1487 (200 mg/m(2)/day was given continuous i.v. via an ambulatory infusion pump throughout the treatment course. A total of 24 @entity1 (15 @entity1 and nine @entity1 ) with advanced @entity1419 between August 1996 and April 2002 were enrolled in this study. RESULTS: Of the 20 evaluable @entity1 , two had partial response (10%) and nine had stable disease (45%), including two minor response. Grade 3/4 @entity1398 was observed in six @entity1 , while grade 3/4 @entity882 was seen in five @entity1 . There was no @entity281 or @entity548 during any of the cycles of chemotherapy. CONCLUSION: ECF regimen is well-tolerated but is not an effective treatment for advanced @entity1419 . Newer clinical trials with combination drugs should be developed.
